Specifically, at first-line EGFR-TKI initiation, and at disease progression in the first-line setting, 44.8% (39/87), and 50.6% (45/89) of patients with metastatic disease had metastasis to bones, 17.2% (15/87), and 23.6% (21/89) had metastasis to the liver, and 14.9% (13/87), and 30.3% (27/89), respectively, had metastasis to the brain (Figure 3). This evidence concerns the gene EGFR and metastatic neoplasm.